134 related articles for article (PubMed ID: 37722956)
21. Effect of oral eliglustat on splenomegaly in patients with Gaucher disease type 1: the ENGAGE randomized clinical trial.
Mistry PK; Lukina E; Ben Turkia H; Amato D; Baris H; Dasouki M; Ghosn M; Mehta A; Packman S; Pastores G; Petakov M; Assouline S; Balwani M; Danda S; Hadjiev E; Ortega A; Shankar S; Solano MH; Ross L; Angell J; Peterschmitt MJ
JAMA; 2015 Feb; 313(7):695-706. PubMed ID: 25688781
[TBL] [Abstract][Full Text] [Related]
22. Real-Life Experience with Oral Eliglustat in Patients with Gaucher Disease Previously Treated with Enzyme Replacement Therapy.
Istaiti M; Becker-Cohen M; Dinur T; Revel-Vilk S; Zimran A
J Clin Med; 2022 Oct; 11(21):. PubMed ID: 36362492
[TBL] [Abstract][Full Text] [Related]
23. Real-world effectiveness of eliglustat in treatment-naïve and switch patients enrolled in the International Collaborative Gaucher Group Gaucher Registry.
Mistry PK; Balwani M; Charrow J; Kishnani P; Niederau C; Underhill LH; McClain MR
Am J Hematol; 2020 Sep; 95(9):1038-1046. PubMed ID: 32438452
[TBL] [Abstract][Full Text] [Related]
24. Eliglustat tartrate for the treatment of adults with type 1 Gaucher disease.
Bennett LL; Turcotte K
Drug Des Devel Ther; 2015; 9():4639-47. PubMed ID: 26345314
[TBL] [Abstract][Full Text] [Related]
25. Gaucher disease and its treatment options.
Bennett LL; Mohan D
Ann Pharmacother; 2013 Sep; 47(9):1182-93. PubMed ID: 24259734
[TBL] [Abstract][Full Text] [Related]
26. Eliglustat maintains long-term clinical stability in patients with Gaucher disease type 1 stabilized on enzyme therapy.
Cox TM; Drelichman G; Cravo R; Balwani M; Burrow TA; Martins AM; Lukina E; Rosenbloom B; Goker-Alpan O; Watman N; El-Beshlawy A; Kishnani PS; Pedroso ML; Gaemers SJM; Tayag R; Peterschmitt MJ
Blood; 2017 Apr; 129(17):2375-2383. PubMed ID: 28167660
[TBL] [Abstract][Full Text] [Related]
27. Plasma glucosylsphingosine correlations with baseline disease burden and response to eliglustat in two clinical trials of previously untreated adults with Gaucher disease type 1.
Peterschmitt MJ; Foster MC; Ji AJ; Zajdel MB; Cox GF
Mol Genet Metab; 2023 Mar; 138(3):107527. PubMed ID: 36739645
[TBL] [Abstract][Full Text] [Related]
28. Glucosylsphingosine is a highly sensitive and specific biomarker for primary diagnostic and follow-up monitoring in Gaucher disease in a non-Jewish, Caucasian cohort of Gaucher disease patients.
Rolfs A; Giese AK; Grittner U; Mascher D; Elstein D; Zimran A; Böttcher T; Lukas J; Hübner R; Gölnitz U; Röhle A; Dudesek A; Meyer W; Wittstock M; Mascher H
PLoS One; 2013; 8(11):e79732. PubMed ID: 24278166
[TBL] [Abstract][Full Text] [Related]
29. Glucosylsphingosine (Lyso-Gb
Gayed MM; Jung SH; Huggins E; Rodriguez-Rassi E; DeArmey S; Kishnani PS; Stiles AR
Int J Mol Sci; 2022 Nov; 23(23):. PubMed ID: 36499264
[TBL] [Abstract][Full Text] [Related]
30. Should eliglustat be first line therapy for patients with type 1 Gaucher disease? Definitions of safety and efficacy.
Zimran A; Goldblatt J; Szer J
Blood Cells Mol Dis; 2018 Feb; 68():14-16. PubMed ID: 28935503
[No Abstract] [Full Text] [Related]
31. A Systematic Review and Meta-analyses of Longitudinal Studies on Drug Treatments for Gaucher Disease.
Leonart LP; Fachi MM; Böger B; Silva MRD; Szpak R; Lombardi NF; Pedroso MLA; Pontarolo R
Ann Pharmacother; 2023 Mar; 57(3):267-282. PubMed ID: 35815393
[TBL] [Abstract][Full Text] [Related]
32. Gaucher Disease Types I and III Responded Well to Substrate Reduction Therapy Using Eliglustat.
Harai N; Ichijo M; Uchinuma H; Hanihara M; Kawaguchi Y; Ichikawa D; Tsuchiya K
Intern Med; 2023 Oct; 62(20):3005-3011. PubMed ID: 36889706
[TBL] [Abstract][Full Text] [Related]
33. Osteonecrosis in Gaucher disease in the era of multiple therapies: Biomarker set for risk stratification from a tertiary referral center.
Basiri M; Ghaffari ME; Ruan J; Murugesan V; Kleytman N; Belinsky G; Akhavan A; Lischuk A; Guo L; Klinger K; Mistry PK
Elife; 2023 May; 12():. PubMed ID: 37249220
[TBL] [Abstract][Full Text] [Related]
34. A Brazilian Rare-Disease Center's Experience with Glucosylsphingosine (lyso-Gb1) in Patients with Gaucher Disease: Exploring a Novel Correlation with IgG Levels in Plasma and a Biomarker Measurement in CSF.
Vernet Machado Bressan Wilke M; Iop GD; Faqueti L; Lemos da Silva LA; Kubaski F; Poswar FO; Michelin-Tirelli K; Randon D; Borelli WV; Giugliani R; Schwartz IVD
Int J Mol Sci; 2024 Mar; 25(5):. PubMed ID: 38474117
[TBL] [Abstract][Full Text] [Related]
35. Eliglustat, an investigational oral therapy for Gaucher disease type 1: Phase 2 trial results after 4 years of treatment.
Lukina E; Watman N; Dragosky M; Pastores GM; Arreguin EA; Rosenbaum H; Zimran A; Angell J; Ross L; Puga AC; Peterschmitt JM
Blood Cells Mol Dis; 2014 Dec; 53(4):274-6. PubMed ID: 24835462
[TBL] [Abstract][Full Text] [Related]
36. Once- versus twice-daily dosing of eliglustat in adults with Gaucher disease type 1: The Phase 3, randomized, double-blind EDGE trial.
Charrow J; Fraga C; Gu X; Ida H; Longo N; Lukina E; Nonino A; Gaemers SJM; Jouvin MH; Li J; Wu Y; Xue Y; Peterschmitt MJ
Mol Genet Metab; 2018 Mar; 123(3):347-356. PubMed ID: 29358012
[TBL] [Abstract][Full Text] [Related]
37. Long-Term Evaluation of Biomarkers in the Czech Cohort of Gaucher Patients.
Malinová V; Poupětová H; Řeboun M; Dvořáková L; Reichmannová S; Švandová I; Murgašová L; Kasper DC; Magner M
Int J Mol Sci; 2023 Sep; 24(19):. PubMed ID: 37833892
[TBL] [Abstract][Full Text] [Related]
38. Enzyme replacement and substrate reduction therapy for Gaucher disease.
Shemesh E; Deroma L; Bembi B; Deegan P; Hollak C; Weinreb NJ; Cox TM
Cochrane Database Syst Rev; 2015 Mar; 2015(3):CD010324. PubMed ID: 25812601
[TBL] [Abstract][Full Text] [Related]
39. Type 1 Gaucher disease (CYP2D6-eliglustat).
Becquemont L
Therapie; 2017 Apr; 72(2):323-326. PubMed ID: 28242126
[TBL] [Abstract][Full Text] [Related]
40. Plasma chitotriosidase activity versus plasma glucosylsphingosine in wide spectrum of Gaucher disease phenotypes - A statistical insight.
Tylki-Szymańska A; Szymańska-Rożek P; Hasiński P; Ługowska A
Mol Genet Metab; 2018 Apr; 123(4):495-500. PubMed ID: 29530534
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
